VIVO Cannabis Inc. V.PDA

RE:import licence

[jayoneill]

couver i follow vivo on many sites and one of the members had the same question here is the response to his questions.

I sent an email to Investor Relations this morning. A couple of hours later, a reply came back. I asked three questions concerning EU-GMP certification. Here it is.

Hi David,



Thanks for your note and kind wishes. My replies to your questions are in red below.



I hope this helps.



Dan





Daniel Weinerman

Director

Good Morning Dan,



I'm a long term shareholder, currently holding over 1.3 million shares. Needless to say, I'm very interested in the company's revenue. Earlier in the year Vivo said it was targeting the second half of 2020 for EU-GMP certification. COVID-19 has caused a delay in this matter. That is a concern because, although I don't believe it's a critical part of the revenue pie, certainly it is a very important one. I have three questions:



Q1. Vivo released it's 3Q20 results and stated that "a follow-up audit" had recently been completed. Is this the final audit or inspection that is required for certification?


A- "The process is multi-faceted so I would think of the follow-up audit as an important step towards EU GMP-certification. It is a requirement to import medical cannabis products from Canada for sale in Germany and other European countries."



Q2. Why, specifically, is the company being delayed with regard to audit/ inspection/ approval?


A- "It is mainly due to COVID-19 given travel restrictions etc… also, VIVO is using German inspection standards, which are known to have the highest standards in the industry."



Q3. Has Vivo ever failed and inspection or audit in the approval process?


A- "My understanding is that this is more consultative in nature, whereby there are certain requirements/comments that the company has to address to the satisfaction of the inspectors versus a pass/fail process."